Drug Development Platforms for ALS
Highlight Urgent Need for Therapies
Highlight Urgent Need for Therapies
Highlight Urgent Need for Therapies
- Neurodegenerative disease patients don’t have effective therapy now and the number of patients is increasing exponentially.
Our Mission
Highlight Urgent Need for Therapies
Highlight Urgent Need for Therapies
- RockGen aims to develop novel therapeutic agents for neurodegenerative diseases, leveraging 20 years of basic neuroscience and preclinical research. Our initial platform focuses on ALS, with broader efforts on Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative disorders.
Developing Anti-Aggregating Drugs
Advancing Neurodegenerative Disease Treatment
Advancing Neurodegenerative Disease Treatment
- Protein abnormalities and clumping (misfolding, oligomerization, and aggregation) are common in neurodegenerative diseases; nothing exists to prevent that. We are focused on developing a solution for this significant problem. Our pre-clinical work aims to discover an effective anti-aggregating class of drugs for this purpose.
Advancing Neurodegenerative Disease Treatment
Advancing Neurodegenerative Disease Treatment
Advancing Neurodegenerative Disease Treatment
- RockGen is focused on disorders involved in progressive loss of structure or function of neurons (neurodegenerative disease) including Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other dementias, Parkinson's disease, Motor neuron diseases, Huntington's disease